Bicalutamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bicalutamide: From Prostate Cancer to Hypertrichosis
One-Sentence Summary
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist, widely used in prostate cancer androgen deprivation therapy but not currently registered in New Zealand. The TxGNN model predicts it may be effective for Hypertrichosis (excessive hair growth), supported by 0 clinical trials and 1 commentary publication — making this primarily a mechanistically plausible but clinically unvalidated hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate cancer (androgen deprivation therapy) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L4 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current evidence pack. Based on established pharmaceutical knowledge, bicalutamide is a competitive non-steroidal androgen receptor (AR) antagonist. It binds AR without activating it, blocking testosterone and dihydrotestosterone (DHT) from triggering androgen-dependent gene transcription. This is the same mechanism exploited in prostate cancer treatment, where androgen signalling drives tumour growth.
Hypertrichosis is a broad term for excessive hair growth beyond what is considered normal for age, sex, and ethnicity. The androgen-dependent subset — including cases triggered or exacerbated by elevated androgens or heightened follicular AR sensitivity — shares direct mechanistic overlap with bicalutamide's pharmacology. In hair follicles responsive to androgens, AR activation promotes miniaturisation reversal and terminal hair production; blocking AR could theoretically suppress this pathway and reduce unwanted hair growth.
The sole supporting publication (PMID 35304167) is a commentary letter in the Journal of the American Academy of Dermatology, commenting on a retrospective review of 35 patients in whom bicalutamide appeared to improve minoxidil-induced hypertrichosis in the setting of female pattern hair loss. While this provides indirect mechanistic plausibility and a small clinical signal, it is tier-3 evidence — an opinion piece rather than a controlled study. The TxGNN model's high score (99.69%) likely reflects strong graph-topology similarity between AR-mediated hair biology nodes rather than accumulated clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35304167 | 2022 | Commentary/Letter | Journal of the American Academy of Dermatology | Commentary on a retrospective review (n=35) in which bicalutamide was observed to improve minoxidil-induced hypertrichosis in female pattern hair loss; highlights AR-blockade as a mechanistic rationale for managing androgen-driven excess hair growth |
Cytotoxicity
Bicalutamide is an antineoplastic agent (hormone therapy for prostate cancer) and is included in cytostatic handling frameworks in most institutional policies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Non-steroidal androgen receptor antagonist (hormone/endocrine therapy); not a conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Low — myelosuppression is not a primary toxicity of bicalutamide; not expected as a dose-limiting concern |
| Emetogenicity Classification | Minimal — oral hormone therapy with very low emetogenic potential |
| Monitoring Items | Liver function tests (LFTs) — hepatotoxicity including fatal cases reported; PSA if used for prostate cancer; CBC at baseline |
| Handling Protection | Standard oral cytostatic/hormone therapy precautions recommended per institutional cytotoxic handling policy; avoid crushing tablets |
Safety Considerations
Please refer to the package insert for safety information. No local (New Zealand/Taiwan) package insert data was available in this evidence pack; consult the originator SmPC or equivalent regulatory labelling from a registered market.
Conclusion and Next Steps
Decision: Hold
Rationale: The only supporting evidence is a single commentary letter describing indirect, retrospective clinical observations; there are no controlled trials and no prospective data specifically evaluating bicalutamide for hypertrichosis. Evidence level L4 is insufficient to advance this indication beyond a hypothesis-generation stage.
To proceed, the following is needed:
- Confirm hypertrichosis subtype: mechanistic link is only plausible for androgen-dependent variants (e.g., minoxidil-induced, idiopathic androgen-excess, hyperandrogenism-related); non-androgenic subtypes (Ambras syndrome, genetic hair shaft abnormalities) are out of scope
- Conduct a prospective pilot study or structured case series in patients with documented androgen-excess hypertrichosis, comparing bicalutamide to standard-of-care (e.g., spironolactone, flutamide)
- Obtain MOA data from DrugBank API to complete the mechanistic link analysis
- Clarify New Zealand (Medsafe) regulatory pathway: off-label prescribing conditions, prescriber obligations, and any data-exclusivity considerations
- Obtain full package insert (SmPC) to complete safety profiling — particularly hepatotoxicity monitoring requirements — before any clinical protocol is designed
Note: Among all 10 TxGNN predictions reviewed in this evidence pack, female breast carcinoma (AR+ TNBC) carries substantially stronger evidence (L2, Phase 2 trial NCT03650894 active, 20 publications including 2025–2026 literature). If prioritisation across indications is being evaluated, the breast cancer signal warrants a separate, higher-priority report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.